Pharmacy Medical News about eosinophilic oesophagitis

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomized, placebo-controlled, double-blind trial
Gut, 10/22/09

Simon HU et al. – Mepolizumab significantly reduced eosinophil numbers in oesophageal tissues in adult patients with active EoE and changes in the expression of molecules associated with oesophageal remodeling were reversed. Minimal clinical improvement was achieved in a subgroup of EoE patients. Mepolizumab had an acceptable safety profile, even at the high 1500 mg dose level.

<< Previous
Visceral fat area is an Independent Predictive Biomarker of...

Next >>
Population pharmacokinetics and optimal design of paediatric...

Audit of eosinophilic oesophagitis in children post-liver transplant
Pediatric Transplantation, 11/06/09 Relevance Score: 64%

Assessment and Reproducibility of Non-Eosinophilic Asthma Using Induced Sputum
Respiration, 10/13/09 Relevance Score: 43%

Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief
Alimentary Pharmacology and Therapeutics, 10/09/09 Relevance Score: 43%

Vitamin D deficiency, eosinophilic esophagitis, and health literacy
Current Opinion in Pediatrics, 10/02/09 Relevance Score: 43%

Differential gene expression and cytokine production from neutrophils in asthma phenotypes
European Respiratory Journal, 10/01/09 Relevance Score: 43%